The System Is Not Optimal!

A conversation with Charles Hsu, Ph.D., Bay City Capital - Part III



00:09:33 - Uploaded by Essinova on February 19, 2009

In this segment, Charles Hsu reflects on the U.S. drug development and commercialization system as a whole, from an investor's point of view.

Mr. Hsu is a Venture Partner at Bay City Capital. He has over 25 years of experience in the life sciences industry, most of which as an entrepreneur and venture capitalist focusing on early-stage life science and health care firms. He has co-founded or invested in over 25 companies, and has served on 15 boards of directors, including Axys Pharmaceuticals, KOSAN, Lexicon Genetics, Biomatrix and Aviron., all of which went public on NASDAQ. Mr. Hsu is active internationally, having worked with several companies in Europe, Israel and Asia. He was a co-founding investor in Asia Renal Care, which became Asia's largest and most profitable independent kidney dialysis provider. He has been a founder, investor, director or advisor with several companies in the Greater China region including Wuxi Pharmatech, Eureka, Progentech and LEAD Therapeutics. Mr. Hsu received his PhD in Genetics and MBA from Stanford University, and an AB degree (Magna cum Laude) in Biochemistry from Harvard. He is frequently invited to speak at conferences and has published articles on the life science opportunities in Asia.

Tags: Charles Hsu, Bay City Capital, FDA


There are 0 comments. You must be logged in to comment.

Opinions & Expertise

 photo Essinova-Brain-and-Mind-banner_iStock_000004422514Medium.jpg

 photo Essinova_Art-and-Science-banner_PIA09962.jpg